Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board

What are you looking for?

  • Anterior Segment
  • Cataract
  • Cornea and External Disease
  • Diabetic Macular Edema
  • Dry Eye
  • Early Onset Cataracts
  • Exclusives
  • General
  • Geographic Atrophy
  • Glaucoma
  • Industry News
  • Inherited Retinal Disease
  • IOLs
  • Neurotrophic Keratitis
  • Ocular Surface Disease
  • Oculoplastics
  • Optometry
  • Pediatrics
  • Practice Management
  • Presbyopia
  • Refractive Surgery/Vision Correction
  • Residents & Young Ophthalmologists
  • Retina
  • Retina Care 360
  • Retinopathy of Prematurity
  • Spotlight Series
  • The Interventional Glaucoma Project
  • The Ophthalmic Project
  • Trending Topics
2nd Annual Photo Contest - Enter Here!
Ophthalmology 360
  • Conferences
  • Videos
  • Podcasts
  • Quizzes
  • About
    • About Us – Mission
    • Content Awards
    • Media Partners
    • Business Team
    • Brand Ambassadors
    • Photo Contest
    • Industry Council
    • Advisory Board
Home > Geographic Atrophy > ARMS2/HTRA1 genotype linked to faster geographic atrophy enlargement
  • Geographic Atrophy

ARMS2/HTRA1 genotype linked to faster geographic atrophy enlargement

Ophthalmology 360

The presence of ARMS2/HTRA1 risk alleles is strongly associated with faster enlargement of geographic atrophy (GA), according to a study. However, this relationship is highly dependent on the initial size of the GA area.

The post hoc analysis of the Age-Related Eye Disease Study 2 (AREDS2) clinical trial included 546 eyes from 406 participants with GA, with a mean age of 73.8 years. Researchers measured GA area using color fundus photographs during annual visits.

The results showed that eyes with ARMS2 risk alleles exhibited considerably faster GA enlargement compared to those without these alleles (P < 0.0001). Specifically, the enlargement rates were 0.224 mm/year, 0.298, and 0.317 for 0-2 risk alleles, respectively.

However, in eyes with a small GA area (<1.9 mm²), the enlargement was significantly accelerated with ARMS2 risk alleles (P < 0.0001), measuring 0.193 mm/year compared to 0.304 for 0 versus 1-2 risk alleles.

In eyes with moderately small (1.9-3.8 mm²) or medium/large (≥3.8 mm²) GA area, the presence of ARMS2 risk alleles did not lead to significantly faster enlargement (P = 0.66 and P = 0.70, respectively). Similarly, ARMS2 genotype did not significantly influence progression to multifocal GA.

Although ARMS2 risk alleles were associated with faster GA enlargement in non-multifocal GA (P = 0.001), the study found no significant association with progression to multifocal GA. The hazard ratios for 1 and 2 risk alleles were 1.03 and 1.12, respectively.

Reference
Agrón E, Domalpally A, Cukras CA, et al; AREDS2 Research Group. Critical Dependence on Area in Relationship between ARMS2/HTRA1 Genotype and Faster Geographic Atrophy Enlargement: AREDS2 Report 33. Ophthalmology. 2023;S0161-6420(23)00670-X. doi: 10.1016/j.ophtha.2023.09.013. Epub ahead of print. PMID: 37717737.

 

This content is independent editorial sponsored by Astellas. Astellas had no input in the development of this content.

Share

Related Content

  • Geographic Atrophy

Geographic atrophy linked to vision loss, higher healthcare costs, and fall risk

  • Geographic Atrophy

Spotlight on IZERVAY®

  • Geographic Atrophy

Two-year GATHER2 data show sustained GA growth reduction with avacincaptad pegol

  • Conference Roundup

Floretina 2025: study shows reduced treatment burden with EYP-1901 for neovascular AMD

3 Mins Watch
  • Geographic Atrophy

Over half of patients with dry AMD developed advanced disease in long-term analysis

  • Geographic Atrophy

Monthly avacincaptad pegol reduces geographic atrophy lesion growth for up to 3.5 years

Share

Editor's Picks

  • Neurotrophic Keratitis

Topical insulin shows real-world benefit in neurotrophic keratopathy

  • Retina

GLP-1 RAs have protective effects against AMD

  • Retina

Four-month injection intervals appear safe for long-term stable nAMD

Advisory Board

Saad Ahmad, MD

Ahmad A. Aref, MD, MBA

Roomasa Channa, MD

David Chow, MD, FRCS(C)

Sally L. Baxter, MD, MSc

Neel R. Desai, MD

Nadia Haqqie, MD

Simon Fung, MD, FRCOphth

Sumit Garg, MD

Ross Lakhanpal, MD, FACS

Sanjai Jalaj, MD

Anton Kolomeyer, MD, PhD

Shan Lin, MD

Steven R. Sarkisian, Jr., MD

See All
Ophthalmology 360

Ophthalmology 360® is a dynamic digital platform dedicated to advancing the field of eye care.

Get to Know Us

  • Home
  • About Us
  • Media Partners
  • Advertising Policy
  • Our Advisory Board

Sign up for our Newsletter

Sign up for our Newsletter to get our newest articles instantly!

  • Privacy Policy
  • Advertising Policy
  • Medical Disclaimer
IHM Logo

2026 Ophthalmology 360 is a trademark of International Healthcare Media, LLC. All rights reserved

  • MedJournal360 Icon
  • RareDisease360 Icon
  • MyHero360 Icon
  • Optometry360 Icon
  • Ophtalmology360 Icon